Table 4 Patient characteristics for each group classified based on the presence or absence of anti-EGFR antibody drug withdrawal, dose reduction, or treatment discontinuation (n = 67)

Sex (male/female)

27/29

7/0

3/1

0.024^a*

Age (years)

63.2 ± 1.48

61.7 ± 3.40

55.0 ± 9.50

0.382^b

Anti-EGFR antibody drug (Cetuximab/Panitumumab)

15/41

2/5

1/3

0.991^a

Height (cm)

162.5 ± 0.98

171.2 ± 2.44

162.8 ± 7.66

0.025^b*

Body weight (kg)

57.9 ± 1.22

71.5 ± 6.29

75.7 ± 9.45

 < 0.001^b*

AST (IU/L)

29.9 ± 3.37

27.6 ± 5.96

22.5 ± 4.35

0.820^b

ALT (IU/L)

22.4 ± 2.96

29.7 ± 5.39

24.3 ± 7.38

0.687^b

T-Bil (mg/dL)

0.50 ± 0.05

0.69 ± 0.15

0.50 ± 0.07

0.405^b

Scr (mg/dL)

0.76 ± 0.03

0.90 ± 0.06

0.68 ± 0.10

0.254^b

Dosage of moisturizer for

1 month after initiation (g)

179.3 ± 13.4

189.3 ± 44.6

106.3 ± 21.3

0.348^b

Minocycline treatment

(Absence/Presence)

28/28

1/6

1/3

0.144^a